Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Effective Interest Rate on Debt % : 44.01% (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Cotinga Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Jan. 2020 was $0.14 Mil. Cotinga Pharmaceuticals's average total debt for the quarter that ended in Jan. 2020 was $0.31 Mil. Therefore, Cotinga Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2020 was 44.01%.

Cotinga Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Cotinga Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Effective Interest Rate on Debt % Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

16.46

2.68

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	2.68	62.80	65.51	44.01

Competitive Comparison of Cotinga Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Effective Interest Rate on Debt % falls into.

Cotinga Pharmaceuticals Effective Interest Rate on Debt % Calculation

Cotinga Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Apr. 2019 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Apr. 2018 )	+	Total Debt (A: Apr. 2019 ))	/ count )
=	-1 * -0.004	/	( (0	+	0.149)	/ 1 )
=	-1 * -0.004	/	0.149
=	2.68 %

where

	Total Debt (A: Apr. 2018 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0
=	0

	Total Debt (A: Apr. 2019 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0.149
=	0.149

Cotinga Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2020 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Oct. 2019 )	+	Total Debt (Q: Jan. 2020 ))	/ count )
=	-1 * -0.136	/	( (0.259	+	0.359)	/ 2 )
=	-1 * -0.136	/	0.309
=	44.01 %

where

	Total Debt (Q: Oct. 2019 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0.259
=	0.259

	Total Debt (Q: Jan. 2020 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0.359
=	0.359

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jan. 2020) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Cotinga Pharmaceuticals (OTCPK:COTQF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Cotinga Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019